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FOXP3 ͉ ROR gamma t ͉ Th17 ͉ Treg ͉ inflammation I L-17 (also known as IL-17A) was identified in 1995 as a cytokine produced by activated human CD45RO ϩ memory T cells (1, 2) . IL-17F, a closely related member with 50% amino acid sequence homology to IL-17A, was later discovered and is also expressed in activated peripheral blood (PB) CD4 ϩ T cells (3) . IL-17 (A and F) induces production of a broad range of proinflammatory cytokines and chemokines, including IL-6, colony-stimulating factors, CXC chemokines, human ␤-defensin-2 and metalloproteinases (4) , by a variety of cells. IL-17 regulates host defense against infectious organisms through promoting granulopoiesis and neutrophil trafficking (5) (6) (7) . In humans, elevated levels of IL-17 have been associated with inflammatory diseases, including rheumatoid arthritis, scleritis, uveitis, asthma, systemic lupus erythematosus, and allograft rejection (8) (9) (10) (11) . In mice, IL-17 contributes to the development of experimental autoimmune encephalomyelitis (12, 13) , collagen-induced arthritis (14, 15) , and colitis (16) . IL-22, a product of IL-17-producing cells, on the other hand, induces acanthosis and psoriasis (17, 18) .
The IL-17-producing CD4 ϩ T helper cells (Th17) cells that produce both IL-17A and IL-17F are now defined as a separate subset (Th17) distinct from the Th1, Th2, and regulatory T (Treg) cells, in terms of developmental regulation and function. Th17 cell differentiation is induced by a combination of IL-6 and TGF-␤ and is augmented by induction of IL-21, which acts in an autocrine manner (19) (20) (21) (22) . Signaling induced by these cytokines results in phosphorylation of STAT3 and expression of the orphan nuclear receptor ROR␥t, transcription factors that are required for induction of IL-17 expression (19, 20, 22) . The maintenance, expansion, and further differentiation of the committed Th17 cells depend on IL-1␤ and IL-23 (19, (23) (24) (25) . The differentiation of naive T cells to Th17 cells can be inhibited by IFN-␥, IL-4, IL-27, IL-2, and retinoic acid, molecules critical for the differentiation of naive CD4 ϩ T cells into Th1, Th2, and Treg cell pathways (13, 19, (26) (27) (28) (29) .
Although human IL-17-producing T cells were originally found enriched in the CD4 ϩ CD45RA Ϫ CD45RO ϩ memory CD4 ϩ T-cell population, it has been unclear whether they overlap with other Th cell subsets, such as Th1, Th2 memory T cells, or Treg T cells. Recently, human Th17 cells were defined as a subpopulation of circulating CD4 ϩ CD45RO ϩ memory T cells that expressed high levels of the chemokine (C-C motif) receptor 6 (CCR6) (30 ϩ Th2 memory cells secreted IL-4, IL-2, and IL-10 but not IFN-␥ or IL-22. In addition, by real-time PCR analyses, we found that Treg cells and CRTH2 Ϫ memory T cells expressed the ROR␥t transcription factor required for Th17 cell differentiation (Fig. 1B) . These 3 T-cell subsets also expressed their lineage-specific transcription factors FOXP3, T-bet, and GATA3, respectively. These data suggest that all CD4 ϩ memory T-cell subsets, including CRTH2 and Treg cells, may contain cells that have the capacity to produce IL-17.
We next investigated the presence of Fig. 2 A and B) . The frequency of the FOXP3 ϩ IL-17 ϩ T cells was 7 times higher in tonsils than in peripheral blood lymphocytes (PBLs). By immunostaining of human tonsil frozen sections, we found the presence of cells expressing FOXP3 only (green) and ROR␥t only (red) as well as both FOXP3 and ROR␥t (gold) (Fig. 2C) (Table S1 ). We next investigated whether the IL-17 ϩ FOXP3 ϩ T-cell clones derived from the CD4 ϩ CD25
high Treg cells maintain suppression function. Fig. 3E shows that both IL-17 ϩ FOXP3 ϩ and the IL-17 Ϫ FOXP3 ϩ T-cell clones potently suppressed the proliferation of CD4 ϩ CD25 Ϫ T cells induced by anti-CD3 and anti-CD28, whereas FOXP3 Ϫ IL-17 ϩ or FOXP3 Ϫ IL-17 Ϫ T-cell clones did not exhibit suppressive activity. To investigate the suppressive mechanisms of these Treg cells, we tested a panel of neutralizing antibodies to IL-10; IL-10R␣; anti-TGF-␤1,2,3; CTLA-4; PD-1; or TGF-␤ inhibitor and found that none of these blocked suppression (data not shown). We next performed transwell experiments and found that the suppressive function of the IL-17 ϩ FOXP3
ϩ Treg clones and IL-17 Ϫ FOXP3 ϩ Treg clones was absent in such conditions, indicating that suppression requires cell-cell contact (Fig. 3F) .
IL-1␤, IL-2, IL-6, IL-21, and IL-23 Act Cooperatively to Induce IL-17
Production by the CCR6 ؊ CD4 ؉ CD25 high Treg Cells. An important question is whether a subpopulation of CD4 ϩ CD25 high Treg cells acquires the ability to produce IL-17 in the thymus during Treg development or in the periphery during inflammatory responses. We therefore isolated T-cell subsets from human thymus and assessed their capacity to produce IL-17 following activation, using flow cytometry and ELISA analyses. We found that
Ϫ CD8 ϩ T cells isolated from thymus failed to secrete detectable amounts of IL-17 upon stimulation with PMA/ ionomycin for 24 h (Fig. 4A) . However, a significant amount of IL-17 was released from the CD4 ϩ CD25 high fraction isolated from PB, suggesting that the FOXP3 ϩ Treg cells may acquire the ability to produce IL-17 in the periphery. To determine whether the peripheral CD4 ϩ CD25
high Treg cells can be induced to differentiate into IL-17 producer cells, we isolated CCR6 Ϫ or CCR6 ϩ CD4 ϩ CD127 Ϫ CD25 high Treg cells from the PB and cultured these cells with anti-CD3, anti-CD28, a low concentration of IL-2, and 10% (vol/vol) human serum (which contains human TGF-␤) in the presence of IL-1␤, IL-6, IL-21, or IL-23 for 15-18 days. We found that IL-2 alone did not induce any Th17 cell differentiation from CCR6 Ϫ CD4 ϩ CD25 high Treg cells (Fig. 4B) , although IL-2 alone or in combination with other cytokines significantly enhanced expansion of Th17 cells from CCR6 ϩ CD4 ϩ CD25 high Treg cells (Fig. 4C) . However, in the presence of IL-1␤, CCR6 Ϫ CD4 ϩ CD25 high Treg cells could produce a low level of IL-17, and their IL-17 production was further enhanced with the addition of IL-6, IL-21, or IL-23 (Fig. 4B) . Flow cytometry analysis of these cells shows that the majority of the IL-17 producer cells are FOXP3 Ϫ (data not shown). These data suggest that IL-1␤ and IL-6 together could induce CCR6 Ϫ CD4 ϩ CD25 high Treg to differentiate into IL-17 producer cells in the presence of human serum.
Discussion
In this study, we have performed a thorough analysis of the ability of CD4 ϩ T-cell subsets from human PB, tonsils, and thymus to produce IL-17. Unexpectedly, we found that up to 3% of FOXP3 ϩ
Treg cells in PB and 25% of FOXP3
ϩ Treg in tonsils have the capacity to produce IL-17 upon activation. We further showed that the IL-17-producing Treg cells preferentially express CCR6, coexpress FOXP3 and ROR␥t, and strongly suppress responder CD4 Treg and Th17 cells (e.g., IL-17 production, CCR6 expression, suppressive activity).
Although FOXP3 ϩ Treg cells are critical for control of autoimmunity and inflammation (34), Th17 cells have been implicated in mediating inflammation and autoimmune diseases (4) . The biological significance of T cells that display the function of Treg and the opposing function of Th17 is unclear. One of the key functions of IL-17 is to promote neutrophil differentiation from hematopoietic progenitor cells and neutrophil trafficking, critical mechanisms for innate immune defense against bacterial and fungal infection. Our finding that some FOXP3
ϩ Treg cells acquire the ability to produce IL-17 suggests that Treg can potentially contribute to the antimicrobial innate immune defense while controlling inflammation and autoimmunity at the same time, particularly at mucosal sites. IFN-␥, a major product of Th1 cells, is critical for the initiation of cell-mediated immunity against intracellular pathogens and the induction of some autoimmune diseases (35, 36) . Interestingly, many IFN-␥-producing Th1 cells were found to produce IL-10, an antiinflammatory cytokine, in antimicrobial immune responses (37) . This phenomenon has been called self-control of Th1 cells, which is a critical mechanism for effective antimicrobial immune responses while limiting self-tissue damage (37) . Indeed, it has been shown that IL-10-deficient mice acutely infected with Toxoplasma gondii induced a lethal Th1 immune response accompanied by overproduction of IL-12, IFN-␥, and TNF-␣ (38) .
In the mouse, the nuclear receptor ROR␥t is expressed in CD4 ϩ CD8 ϩ thymocytes but not in single-positive CD4 or CD8 thymocytes (39) . Accordingly, we did not detect any IL-17 produced by the single-positive thymic T-cell populations tested, including the FOXP3 ϩ Treg thymocytes. There was also no IL-17 produced by human double-positive thymocytes, suggesting that the expression of ROR␥t is insufficient for T-lineage cells to acquire the ability to produce IL-17 in thymus. Our data suggest that peripheral CCR6 Ϫ CD4 ϩ CD25 high Treg cells stimulated in the presence of IL-1␤ and IL-6 differentiated into IL-17 producer cells in the presence of 10% (vol/vol) human serum, which contains TGF-␤ critical for human Th17 differentiation (40) . This, together with the finding that a significant number of Treg cells in PB and particularly in tonsils produce IL-17, suggests that the IL-17 ϩ FOXP3
ϩ Treg cells are generated at mucosal sites during inflammation. Indeed, a recent study in mice by Zhou et al. (41) has demonstrated the presence of FOXP3 ϩ ROR␥t ϩ T cells that have the ability to produce IL-17 in the lamina propria of the small intestine. The identification of IL-17-producing FOXP3 ϩ Treg cells in both mice and humans suggests that Th17 and FOXP3 ϩ Treg lineages are related in ontogeny. Both lineages appear to depend on TGF-␤ for their differentiation and/or maintenance, and additional cytokines may determine whether they become Th17, Treg, or dual-function effector T cells (41) . FOXP3 ϩ Treg cells may thus actively contribute to antimicrobial innate immunity by producing IL-17, while they control inflammation and autoimmunity at the same time.
Materials and Methods
Purification of CD4 ؉ T-Cell Subsets. Adult blood buffy coats from healthy donors were obtained from the Gulf Coast Regional Blood Center in Texas. CD4 ϩ T cells were enriched using a CD4 T-cell isolation kit (Miltenyi Biotec) according to manufacturer's procedures. We isolated CRTH2 T cells from enriched CD4 ϩ T cells by staining with biotin-CRTH2 antibody, followed by biotin-microbeads. Flow-through cells from LS column (Miltenyi Biotec) were stained with streptavidin-PE, APC-Cy7-CD4 antibody, and FITC-labeled lineage mixture antibodies against CD14, CD16, CD19, CD56, CD11c, and ␥␦-TCR and were sorted on a FACSAria (BD Bioscience) into a single fraction of CD4 ϩ CRTH2 ϩ . Cells retained in the LS column were eluted and stained with same FITC-labeled lineage mixture antibodies plus APC-Cy7-CD4, PE-Cy7-CD25, PE-CD127, and biotin-CD45RA and were then washed and stained with streptavidin-perCP-Cy5.5. Stained cells were sorted into 3 fractions of CD127 Ϫ CD4 ϩ CD25 high (top 2-3%, average of 90% FOXP3 ϩ ) Treg cells, CD4 ϩ CD25 low CD45RA ϩ naive T cells, and CD4 ϩ CD25 low CD45RA Ϫ CRTH2 Ϫ memory T cells.
Treg Cell Culture. CCR6 ϩ or CCR6 Ϫ CD4 ϩ CD25 high Treg cells were cultured for 5-6 days in 96-well flat-bottomed plates (Falcon) at a cell density of 5 ϫ 10 4 cells per well in RPMI 1640 medium containing 10% (vol/vol) human AB serum (GemCell), 40 IU/mL IL-2, neutralizing anti-IFN-␥ (5 g/mL; 25718; R&D Systems), and anti-IL-4 (5 g/mL; R&D Systems), along with plate-bound anti-CD3 (2 g/mL) and soluble anti-CD28 (1 g/mL). Where indicated, IL-1␤ (10 ng/mL), IL-6 (20 ng/mL), IL-21 (50 ng/mL), or IL-23 (20 ng/mL) was added to the cultures. Fresh culture medium containing the indicated cytokines was added every 5-6 days. On days 15-18, 5 ϫ 10 4 cells were stimulated with plate-bound anti-CD3 (2 g/mL) and anti-CD28 (1 g/mL) and analyzed for IL-17 cytokine release.
Generation of Human PBL-Derived CD4 ؉ Treg Cell Clones. CD4 ϩ T-cell clones were generated from flow cytometry-sorted CD4 ϩ CD25 high (top 2%) cells by limiting dilution methods as described (42) using 0.5 T cell per well and 5 ϫ 10 4 cells per well of irradiated allogeneic peripheral blood mononuclear cells (PBMCs; 7,000 rad) as feeder cells in lymphocyte stimulation medium containing RPMI 1640 (Invitrogen) supplemented with 2 mmol/L L-glutamine, 0.05 mmol/L ␤-mercaptoethanol, 10% human male AB serum (GemCell), 300 IU/mL IL-2, 75 ng/mL anti-CD3, 15 ng/mL anti-CD28, and 100 ng/mL anti-inducible T cell costimulator (ICOS). On day 14, one-fifth of the cells from each well with cell outgrowth were washed and restimulated with 3 g/mL plate-bound anti-CD3 and 1 g/mL soluble anti-CD28 in T-cell assay medium containing RPMI 1640 plus 4% (vol/vol) human AB serum and 2 mmol/L L-glutamine. IL-17 release from T cells was measured by ELISA. High IL-17 producer cells were then expanded, as previously described (42) , using the same lymphocyte stimulation medium as above but supplemented with irradiated allogeneic 1.6 million/mL PBMCs (irradiation with 7,000 rad) and 0.3 million/mL EBV B-cell lines LCL111 and 112 (23,000 rad). Th17 T-cell clones derived from CD4 ϩ CD25 low cells were generated as above, except that 5 ng/mL IL-1␤ and 10 ng/mL IL-23 were added in the expansion medium. The clonality of T-cell clones was determined with RT-PCR or monoclonal antibodies against the V␤ regions. All T cells were confirmed to be free of mycoplasma by a PlasmoTest kit (InvivoGen).
For more information, see SI Matierals and Methods.
Statistical Analysis. A standard two-tailed t test was used for statistical analysis with P values of 0.05 or less considered significant.
